Can tribulus terrestris cause gynaecomastia? It is a question increasingly asked by men using this popular herbal supplement for testosterone support or athletic performance. Tribulus terrestris is widely sold in the UK as a food supplement, yet its hormonal effects remain poorly understood and its clinical evidence base is inconsistent. Whilst no regulatory body has established a definitive causal link between tribulus terrestris and gynaecomastia, theoretical mechanisms and supplement quality concerns mean the question deserves careful, evidence-based consideration. This article examines what is currently known.

What Is Tribulus Terrestris and How Is It Used in the UK

Tribulus terrestris is a herbal supplement sold widely in the UK as capsules, tablets, and powders, regulated as a food supplement by the FSA rather than as a licensed medicine, with no requirement to prove efficacy before sale.

Tribulus terrestris is a flowering plant native to warm, tropical regions of Europe, Asia, Africa, and Australia. It has been used for centuries in traditional Ayurvedic and Chinese medicine, primarily to support male vitality, urinary health, and libido. In the UK today, it is widely marketed as a natural sports supplement, often promoted for its purported ability to boost testosterone levels, enhance athletic performance, and support muscle growth.

In the UK, tribulus terrestris is almost always sold as a food supplement — in capsule, tablet, and powder form — through health food shops, gyms, and online retailers. As a food supplement, it falls primarily under UK food law and is overseen by the Food Standards Agency (FSA), not the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA's Traditional Herbal Registration (THR) scheme applies specifically to traditional herbal medicinal products; the vast majority of tribulus terrestris products on the UK market are not THR-registered and therefore do not carry that quality and safety mark. Whilst food supplements must still comply with food safety and labelling legislation, manufacturers are not required to demonstrate efficacy or obtain pre-market authorisation as they would for a licensed medicine.

The plant's active compounds are believed to include steroidal saponins — particularly protodioscin — which some researchers have suggested may influence hormone pathways. However, randomised controlled trials (RCTs) in healthy men and athletes have generally found no meaningful increase in testosterone levels or physical performance with tribulus terrestris supplementation (Neychev & Mitev, J Ethnopharmacol 2005; Rogerson et al., Int J Sport Nutr Exerc Metab 2007). The clinical evidence supporting its testosterone-boosting claims remains inconsistent and largely inconclusive.

Despite this, tribulus terrestris remains one of the most popular herbal supplements among men seeking performance enhancement or hormonal support. Competitive athletes should be aware that some supplement products carry a risk of contamination with undisclosed substances, including those prohibited under anti-doping rules. UK Anti-Doping (UKAD) advises athletes to use products certified by a recognised third-party testing programme such as Informed Sport, and to consult UKAD guidance before using any supplement.

Understanding Gynaecomastia: Causes and Risk Factors

Gynaecomastia is benign male breast glandular enlargement caused by an oestrogen-to-androgen imbalance; causes include medications, anabolic steroids, herbal supplements, and underlying conditions such as hypogonadism or testicular tumours.

Gynaecomastia refers to the benign enlargement of glandular breast tissue in males, resulting from an imbalance between oestrogen and androgen activity in breast tissue. It is distinct from pseudogynaecomastia, which involves fatty tissue accumulation without true glandular proliferation. Gynaecomastia can affect one or both breasts and may present with tenderness, firmness, or a palpable disc of tissue beneath the nipple.

The condition is relatively common across different life stages. It occurs physiologically in neonates, adolescents, and older men due to natural hormonal fluctuations. However, pathological gynaecomastia can arise from a range of causes, including:

• Hormonal imbalances — elevated oestrogen or reduced androgen levels

• Medications — including anabolic steroids, anti-androgens (e.g., bicalutamide, finasteride), spironolactone, ketoconazole, digoxin, cimetidine, some antidepressants, and certain antiretrovirals

• Recreational drugs and alcohol — cannabis has been associated with breast tissue changes, though the evidence is of limited quality; associations with heroin and amphetamines are similarly uncertain

• Underlying medical conditions — such as hypogonadism (including Klinefelter's syndrome), hyperthyroidism, liver cirrhosis, or testicular tumours

• Herbal and dietary supplements — some plant-based products contain phyto-oestrogenic compounds

From a pharmacological standpoint, gynaecomastia develops when the oestrogen-to-androgen ratio in breast tissue shifts in favour of oestrogenic activity, stimulating ductal and stromal proliferation. This can occur through increased oestrogen production, decreased androgen levels, or enhanced sensitivity of breast tissue receptors.

It is important to distinguish benign gynaecomastia from male breast cancer. Red flags that warrant urgent assessment include a hard or irregular unilateral mass, skin or nipple changes (such as tethering, ulceration, or nipple inversion), and palpable axillary lymph nodes. These features should prompt urgent referral in line with NICE guidance (NG12). Understanding the causes and risk factors for gynaecomastia is important when evaluating whether supplements such as tribulus terrestris could plausibly contribute to breast tissue changes in susceptible individuals.

Evidence Linking Tribulus Terrestris to Gynaecomastia

No established causal link between tribulus terrestris and gynaecomastia is recognised by the MHRA or EMA; the proposed conversion of saponins to oestrogenic precursors remains a theoretical mechanism unconfirmed in controlled human trials.

The direct question of whether tribulus terrestris can cause gynaecomastia is not straightforwardly answered by current clinical evidence. There is no established causal link between tribulus terrestris supplementation and gynaecomastia recognised by regulatory bodies such as the MHRA or the European Medicines Agency (EMA). However, this does not entirely rule out a plausible biological mechanism or individual susceptibility.

Some researchers have proposed that the steroidal saponins in tribulus terrestris — particularly protodioscin — may be converted in the body to dehydroepiandrosterone (DHEA), a precursor hormone that can be metabolised into both androgens and oestrogens. It is important to note that this conversion pathway has not been reliably demonstrated in robust human clinical studies; it remains a theoretical mechanism and should not be taken as established fact. If such a pathway were to favour oestrogen production in certain individuals, it could theoretically shift hormonal balance, but this has not been confirmed in controlled trials.

RCTs conducted in healthy men and athletes have generally not demonstrated meaningful changes in testosterone or androgen status with tribulus terrestris supplementation (Neychev & Mitev, J Ethnopharmacol 2005; Rogerson et al., Int J Sport Nutr Exerc Metab 2007). Peer-reviewed case reports specifically attributing gynaecomastia to tribulus terrestris are lacking in the published literature; anecdotal accounts exist but are insufficient to establish causality, particularly as many users take multiple supplements simultaneously, making it difficult to isolate any single product as a contributing factor.

A further consideration is supplement quality. Products labelled as tribulus terrestris may contain undisclosed ingredients or contaminants — a concern highlighted by MHRA safety communications regarding unlicensed herbal products. UKAD similarly warns that supplement contamination is a recognised risk. Until higher-quality evidence is available, any reported association between tribulus terrestris and gynaecomastia should be treated with caution, whilst acknowledging that individual hormonal responses to plant-based compounds can vary.

When to Seek Medical Advice About Breast Tissue Changes

Any new breast lump, persistent tenderness, nipple discharge, or rapid asymmetrical breast change in a male warrants prompt GP assessment; a hard or irregular unilateral mass should trigger an urgent two-week-wait referral under NICE NG12.

Any noticeable change in breast tissue in a male — including swelling, tenderness, firmness, or the appearance of a lump beneath the nipple — warrants prompt medical evaluation. Whilst gynaecomastia is most commonly benign, it is important to rule out more serious underlying causes, including testicular cancer, adrenal tumours, or other endocrine disorders.

You should contact your GP if you experience:

• A new or growing lump in one or both breasts

• Breast pain or tenderness that is persistent or worsening

• Nipple discharge of any kind

• Asymmetrical breast changes that develop rapidly

• Systemic symptoms such as unexplained weight loss, fatigue, or testicular changes occurring alongside breast tissue enlargement

In line with NICE guidance (NG12: Suspected Cancer — Recognition and Referral), a hard or irregular unilateral breast mass, nipple changes, or palpable axillary lymphadenopathy in a male should prompt consideration of an urgent two-week-wait referral to exclude male breast cancer.

Your GP will typically take a thorough medical and medication history — including any supplement use — and may arrange blood tests to assess hormone levels (including testosterone, oestradiol, LH, FSH, prolactin, and beta-hCG where a tumour is suspected), as well as liver function and thyroid function tests. Sex hormone-binding globulin (SHBG) may also be measured. Where a testicular mass is palpable or tumour markers are raised, testicular ultrasound is indicated. In line with NICE CKS guidance on gynaecomastia, referral to an endocrinologist or breast specialist may be appropriate depending on findings. It is worth noting that long-standing gynaecomastia (present for more than 12 months) tends to be more fibrotic and less likely to resolve spontaneously, making early assessment preferable.

If you are currently taking tribulus terrestris or any other herbal supplement and notice breast changes, it is advisable to discontinue use and inform your GP. Do not stop any prescribed medication without medical advice. Transparency about supplement use is essential, as many patients do not consider herbal products relevant to disclose during consultations, yet they can have meaningful physiological effects and interact with other treatments.

Safer Alternatives and MHRA Guidance on Herbal Supplements

The MHRA advises caution with unlicensed herbal products, particularly those bought online; adverse reactions can be reported via the Yellow Card Scheme, and evidence-based lifestyle measures are preferable to unproven supplements for hormonal support.

For individuals seeking to support testosterone levels, athletic performance, or general wellbeing, it is worth approaching herbal supplements with informed caution. In the UK, the MHRA's Traditional Herbal Registration (THR) scheme provides a quality and safety standard for traditional herbal medicinal products; consumers can look for the THR certification mark as a basic quality indicator. However, it is important to understand that most tribulus terrestris products sold in the UK are marketed as food supplements rather than traditional herbal medicines, and are therefore not eligible for — and do not carry — a THR mark. These products are regulated under UK food law, overseen by the FSA, which requires safety and accurate labelling but does not require proof of efficacy.

The MHRA has issued broader guidance advising the public to exercise caution with unlicensed herbal products, particularly those purchased online or from unregulated sources, as these may contain undisclosed active ingredients, contaminants, or inaccurate dosage information. Products marketed specifically for testosterone boosting or muscle enhancement are a particular area of concern, as they may contain prohormones or other compounds not listed on the label.

If you believe you have experienced a side effect from a herbal remedy or food supplement — including any breast tissue changes — you can report this to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk. Reporting suspected adverse reactions helps the MHRA monitor the safety of these products and take action where necessary.

For competitive athletes, UKAD advises using supplements that have been tested by a recognised third-party certification programme such as Informed Sport, and consulting UKAD's guidance on supplement risks before use, to minimise the risk of inadvertent anti-doping rule violations from contaminated products.

Safer, evidence-based approaches to supporting hormonal health and physical performance include:

• Optimising lifestyle factors — regular resistance exercise, adequate sleep, and a balanced diet rich in zinc, vitamin D, and healthy fats are all associated with healthy testosterone levels

• Consulting a registered dietitian or sports nutritionist — for personalised, evidence-based supplementation advice

• Discussing concerns with a GP — particularly if hormonal symptoms such as fatigue, reduced libido, or mood changes are present, as these may indicate an underlying condition requiring investigation

In summary, whilst there is no definitive clinical proof that tribulus terrestris directly causes gynaecomastia, the unproven hormonal mechanisms, variability in supplement quality, and potential for undisclosed ingredients mean that caution is warranted. Individuals experiencing breast tissue changes whilst using any supplement should seek prompt medical review rather than self-managing the condition.

Frequently Asked Questions